Jerry Gurwitz to Drug Labeling
This is a "connection" page, showing publications Jerry Gurwitz has written about Drug Labeling.
Connection Strength
0.942
-
Briesacher BA, Soumerai SB, Zhang F, Toh S, Andrade SE, Wagner JL, Shoaibi A, Gurwitz JH. A critical review of methods to evaluate the impact of FDA regulatory actions. Pharmacoepidemiol Drug Saf. 2013 Sep; 22(9):986-94.
Score: 0.433
-
Mazor KM, Andrade SE, Auger J, Fish L, Gurwitz JH. Communicating safety information to physicians: an examination of dear doctor letters. Pharmacoepidemiol Drug Saf. 2005 Dec; 14(12):869-75.
Score: 0.255
-
Tjia J, Fischer SH, Raebel MA, Peterson D, Zhao Y, Gagne SJ, Gurwitz JH, Field TS. Baseline and follow-up laboratory monitoring of cardiovascular medications. Ann Pharmacother. 2011 Sep; 45(9):1077-84.
Score: 0.095
-
Walsh KE, Mazor KM, Stille CJ, Torres I, Wagner JL, Moretti J, Chysna K, Stine CD, Usmani GN, Gurwitz JH. Medication errors in the homes of children with chronic conditions. Arch Dis Child. 2011 Jun; 96(6):581-6.
Score: 0.092
-
Wagner AK, Chan KA, Dashevsky I, Raebel MA, Andrade SE, Lafata JE, Davis RL, Gurwitz JH, Soumerai SB, Platt R. FDA drug prescribing warnings: is the black box half empty or half full? Pharmacoepidemiol Drug Saf. 2006 Jun; 15(6):369-86.
Score: 0.066